» Articles » PMID: 34670828

High Endothelial Venule is a Surrogate Biomarker for T-cell Inflamed Tumor Microenvironment and Prognosis in Gastric Cancer

Overview
Date 2021 Oct 21
PMID 34670828
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High endothelial venule (HEV) is a specialized vasculature for lymphocyte trafficking. While HEVs are frequently observed within gastric cancer (GC), the vascular-immune interaction between HEV and tumor-infiltrating lymphocytes (TILs) has not been well elucidated. In this study, we aimed to unveil the potential value of HEVs as a surrogate marker for T-cell inflamed immune microenvironment in GC using a large number of prospectively collected surgical specimens of GC.

Methods: We included 460 patients with GC who underwent surgical resection. Nanostring PanCancer immune profiling was performed to evaluate the immunological phenotype of GCs. HEV density and three distinct patterns of TILs (Crohn-like lymphoid reaction, peritumoral lymphoid reaction, and intratumoral lymphoid reaction) were analyzed for their relationship and evaluated as prognostic factors for relapse-free survival (RFS) and overall survival (OS).

Results: HEV-high GC revealed increased infiltration by immune cell subsets, including dendritic cells, CD8 cytotoxic T cells, and CD4 helper T cells. In addition, HEV-high GC demonstrated increased immune-modulating chemokines, type I or II interferon pathway, and immune checkpoints, all of which indicate the inflamed tumor microenvironment (TME). All three distinct patterns of TILs were associated with HEV density. In survival analysis, patients with HEV-high GC displayed significantly longer RFS and OS than those with HEV-low GC (p<0.001 for RFS, p<0.001 for OS). Multivariate analysis demonstrated that HEV was the most significant immunological prognostic factor for RFS (patients with high HEV compared with those with low HEV; HR 0.412, 95% CI 0.241 to 0.705, p=0.001) and OS (HR 0.547, 95% CI 0.329 to 0.909, p=0.02) after adjustment for age, stage, and TIL.

Conclusion: HEV is the most significant immunological prognosticator for RFS and OS in resected GC, indicating inflamed TME.

Citing Articles

Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.

Chen W, Zhang L, Gao M, Zhang N, Wang R, Liu Y Front Immunol. 2025; 15():1519034.

PMID: 39840050 PMC: 11747648. DOI: 10.3389/fimmu.2024.1519034.


Maturation of Tertiary Lymphoid Structures.

Shu D, Sidiropoulos D Methods Mol Biol. 2024; 2864:43-55.

PMID: 39527216 DOI: 10.1007/978-1-0716-4184-2_3.


Recent clinical researches and technological development in TIL therapy.

Matsueda S, Chen L, Li H, Yao H, Yu F Cancer Immunol Immunother. 2024; 73(11):232.

PMID: 39264449 PMC: 11393248. DOI: 10.1007/s00262-024-03793-4.


Intratumoral high endothelial venules in solid tumors: a pooled study.

Wang B, Han Y, Liu J, Zhang X, Deng Y, Jiang Y Front Immunol. 2024; 15:1401118.

PMID: 39040120 PMC: 11260642. DOI: 10.3389/fimmu.2024.1401118.


DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images.

Tian M, Yao Z, Zhou Y, Gan Q, Wang L, Lu H J Transl Med. 2024; 22(1):182.

PMID: 38373959 PMC: 10877826. DOI: 10.1186/s12967-023-04838-5.


References
1.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

2.
Madej-Michniewicz A, Budkowska M, Salata D, Dolegowska B, Starzynska T, Blogowski W . Evaluation of selected interleukins in patients with different gastric neoplasms: a preliminary report. Sci Rep. 2015; 5:14382. PMC: 4613562. DOI: 10.1038/srep14382. View

3.
Hennequin A, Derangere V, Boidot R, Apetoh L, Vincent J, Orry D . Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016; 5(2):e1054598. PMC: 4801425. DOI: 10.1080/2162402X.2015.1054598. View

4.
Ogino S, Nosho K, Irahara N, Meyerhardt J, Baba Y, Shima K . Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; 15(20):6412-20. PMC: 2771425. DOI: 10.1158/1078-0432.CCR-09-1438. View

5.
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M . Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunol Res. 2019; 7(5):737-750. DOI: 10.1158/2326-6066.CIR-18-0436. View